Sudeep Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
228.00
182.00
174.00
85.00
68.00
43.00
Adjustment
9.00
15.00
13.00
17.00
5.00
4.00
Changes In working Capital
-112.00
-109.00
-77.00
-33.00
-59.00
-1.00
Cash Flow after changes in Working Capital
125.00
89.00
110.00
70.00
14.00
45.00
Cash Flow from Operating Activities
69.00
48.00
65.00
48.00
-2.00
35.00
Cash Flow from Investing Activities
-326.00
-78.00
-49.00
-49.00
-38.00
-40.00
Cash Flow from Financing Activities
247.00
52.00
-12.00
-9.00
50.00
13.00
Net Cash Inflow / Outflow
-10.00
22.00
3.00
-11.00
9.00
7.00
Opening Cash & Cash Equivalents
36.00
13.00
10.00
21.00
11.00
4.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
26.00
36.00
13.00
10.00
21.00
11.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Sudeep Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
228.07
3675.03
-3,447.00
-93.79%
Adjustment
9.02
-2893.97
2,902.00
100.31%
Changes In working Capital
-112.07
-163.73
51.00
31.55%
Cash Flow after changes in Working Capital
125.03
617.34
-492.00
-79.75%
Cash Flow from Operating Activities
69.55
684.37
-615.00
-89.84%
Cash Flow from Investing Activities
-326.91
-90.25
-236.00
-262.23%
Cash Flow from Financing Activities
247.29
-642.58
889.00
138.48%
Net Cash Inflow / Outflow
-10.07
-48.46
38.00
79.22%
Opening Cash & Cash Equivalents
36.81
161.02
-125.00
-77.14%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
26.74
112.56
-86.00
-76.24%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 42.73% vs -25.82% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
69.55
48.73
42.73%






